Roche Executive: Herceptin Still Has Growth Potential
March 11 2009 - 9:48AM
Dow Jones News
Roche Holding AG (ROG.VX) is confident that Herceptin still has
still potential to expand sales more, Peter Brown, life cycle
leader for the breast cancer drug said Wednesday.
Herceptin had sales of CHF5.1 billion in 2008.
Company Web site: www.roche.com
-By Anita Greil, Dow Jones Newswires; +41 43 443 8044 ;
anita.greil@dowjones.com